Södertälje, Sweden

Joakim Bergman

This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Joakim Bergman. Retrieved from https://idiyas.com/inventor/joakim-bergman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 50.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Joakim Bergman: Innovator in GLP-1 Receptor Modulation

Introduction

Joakim Bergman is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate GLP-1 receptors. His work is crucial in addressing various metabolic conditions, including Type 2 diabetes.

Latest Patents

Bergman holds a patent for "Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as GLP-1 receptor modulators." This patent discloses certain 2,5-diazabicyclo[4.2.0]octanes of formula (I) and octahydrofuro[3,4-b]pyrazines, along with their pharmaceutically acceptable salts. The patent also includes compositions containing these compounds and their therapeutic uses. These compounds are particularly useful in the treatment or prophylaxis of cardiovascular diseases and metabolic conditions.

Career Highlights

Bergman is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to innovative solutions in healthcare, particularly in the management of chronic diseases.

Collaborations

Bergman collaborates with Johan Sundell, enhancing the research and development efforts within their team. Their combined expertise fosters innovation in the pharmaceutical industry.

Conclusion

Joakim Bergman is a prominent inventor whose work in GLP-1 receptor modulation has the potential to significantly impact the treatment of metabolic diseases. His contributions to AstraZeneca and the field of pharmaceuticals highlight the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…